New Delhi, Jan 25 (Agencies): Drug firm Aurobindo Pharma on Tuesday said it has received approval from the US health regulator to manufacture and market generic levofloxacin tablets, used for treating bacterial infections, in the American market.

The company has received the tentative approval from US Food and Drug Administration to manufacture and market levofloxacin tablets in the strengths of 250 mg, 500 mg and 750 mg, Aurobindo said in a statement.

According to IMS Health sales data, levofloxacin tablets had a market size of nearly USD 1.45 billion for the 12 months ending September last year.

The levofloxacin tablets are generic equivalent of Ortho MacNeil Janssen Pharmaceutical Inc's 'Levaquin' tablets and are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms such as pneumonia, bacterial sinusitis and chronic bronchitis.

Shares of Aurobindo Pharma were trading at Rs 1,262 on Bombay Stock Exchange on Tuesday trade, down 0.11 per cent from its previous close.